174 related articles for article (PubMed ID: 23677467)
1. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.
Carmenate T; Pacios A; Enamorado M; Moreno E; Garcia-Martínez K; Fuente D; León K
J Immunol; 2013 Jun; 190(12):6230-8. PubMed ID: 23677467
[TBL] [Abstract][Full Text] [Related]
2. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
Front Immunol; 2022; 13():974188. PubMed ID: 36059465
[TBL] [Abstract][Full Text] [Related]
3. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
4. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G
Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191
[TBL] [Abstract][Full Text] [Related]
5. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.
Shanafelt AB; Lin Y; Shanafelt MC; Forte CP; Dubois-Stringfellow N; Carter C; Gibbons JA; Cheng SL; Delaria KA; Fleischer R; Greve JM; Gundel R; Harris K; Kelly R; Koh B; Li Y; Lantz L; Mak P; Neyer L; Plym MJ; Roczniak S; Serban D; Thrift J; Tsuchiyama L; Wetzel M; Wong M; Zolotorev A
Nat Biotechnol; 2000 Nov; 18(11):1197-202. PubMed ID: 11062441
[TBL] [Abstract][Full Text] [Related]
6. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model.
Elzaouk L; Moelling K; Pavlovic J
Exp Dermatol; 2006 Nov; 15(11):865-74. PubMed ID: 17002683
[TBL] [Abstract][Full Text] [Related]
12. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
14. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
16. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT
Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and antitumor activity of a mutant type of interleukin 2.
Dehghan R; Beig Parikhani A; Zeinali S; Shokrgozar M; Amanzadeh A; Ajdary S; Ahangari Cohan R; Talebkhan Y; Behdani M
Sci Rep; 2022 Mar; 12(1):5376. PubMed ID: 35354847
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
